Clinical significance of gastrointestinal and flushing events in patients with multiple sclerosis treated with delayed-release dimethyl fumarate

International Journal of MS Care

Volumn 17, Issue 5, 2015, Pages 236-243

  Phillips, J Theodore ^a   Selmaj, Krzysztof ^b   Gold, Ralf ^c   Fox, Robert J ^d   Havrdova, Eva ^e   Giovannoni, Gavin ^f   Abourjaily, Heather ^g   Pace, Amy ^g   Novas, Mark ^g   Hotermans, Christophe ^g   Viglietta, Vissia ^g   Meltzer, Leslie ^g  

^a BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c ST JOSEF HOSPITAL   (Germany)

^d LERNER RESEARCH INSTITUTE   (United States)

^e CHARLES UNIVERSITY   (Czech Republic)

^f QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^g BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84945252500     PISSN: 15372073     EISSN: None     Source Type: Journal    
DOI: 10.7224/1537-2073.2014-069     Document Type: Article

References (9)

1. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367:1098-1107.
2. Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis [published correction appears in N Engl J Med. 2012;367:1673]. N Engl J Med. 2012;367:1087-1097.
3. Bar-Or A, Gold R, Kappos L, et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. J Neurol. 2013;260:2297-2305.
4. Hutchinson M, Fox RJ, Miller DH, et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. J Neurol. 2013;260:2286-2296.
5. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria." Ann Neurol. 2005;58:840-846.
6. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444-1452.
7. International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonized tripartite guideline: Guideline for Good Clinical Practice. J Postgrad Med. 2001;47:45-50.
8. World Medical Association. Declaration of Helsinki. Ferney-Voltaire, France: World Medical Association; June 1964.
9. Phillips JT, Hutchinson M, Fox R, Gold R, Havrdova E. Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: experiences of an international panel. Mult Scler Relat Disord. 2014;3:513-519.